The identification of vascular endothelial growth factor (VEGF) polymorphisms in late-stage AMD has led to the use of optical coherence tomography-guided anti-VEGF (OCTVEGF) treatments which slow disease progression by treating CNV [143]. Here, VEGFA is linked to age-related macular degeneration.